Annual EBITDA
-$51.61 M
-$8.92 M-20.89%
December 31, 2023
Summary
- As of February 12, 2025, ABOS annual EBITDA is -$51.61 million, with the most recent change of -$8.92 million (-20.89%) on December 31, 2023.
- During the last 3 years, ABOS annual EBITDA has fallen by -$43.69 million (-552.25%).
- ABOS annual EBITDA is now -561.19% below its all-time high of -$7.80 million, reached on December 31, 2019.
Performance
ABOS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$28.69 M
-$9.21 M-47.23%
September 30, 2024
Summary
- As of February 12, 2025, ABOS quarterly EBITDA is -$28.69 million, with the most recent change of -$9.21 million (-47.23%) on September 30, 2024.
- Over the past year, ABOS quarterly EBITDA has dropped by -$15.78 million (-122.13%).
- ABOS quarterly EBITDA is now -2038.08% below its all-time high of -$1.34 million, reached on December 1, 2020.
Performance
ABOS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$77.89 M
-$15.78 M-25.40%
September 30, 2024
Summary
- As of February 12, 2025, ABOS TTM EBITDA is -$77.89 million, with the most recent change of -$15.78 million (-25.40%) on September 30, 2024.
- Over the past year, ABOS TTM EBITDA has dropped by -$30.34 million (-63.81%).
- ABOS TTM EBITDA is now -3706.79% below its all-time high of -$2.05 million, reached on March 31, 2020.
Performance
ABOS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ABOS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -20.9% | -122.1% | -63.8% |
| 3 y3 years | -552.3% | -148.3% | -69.5% |
| 5 y5 years | -561.2% | -148.3% | -69.5% |
ABOS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -163.6% | at low | -241.1% | at low | -297.8% | at low |
| 5 y | 5-year | -561.2% | at low | -2038.1% | at low | -3706.8% | at low |
| alltime | all time | -561.2% | at low | -2038.1% | at low | -3706.8% | at low |
Acumen Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$28.69 M(+47.2%) | -$77.89 M(+25.4%) |
| Jun 2024 | - | -$19.49 M(+40.9%) | -$62.11 M(+14.6%) |
| Mar 2024 | - | -$13.83 M(-12.9%) | -$54.18 M(+5.0%) |
| Dec 2023 | -$51.61 M(+20.9%) | -$15.88 M(+22.9%) | -$51.61 M(+8.5%) |
| Sep 2023 | - | -$12.92 M(+11.8%) | -$47.55 M(+3.5%) |
| Jun 2023 | - | -$11.56 M(+2.7%) | -$45.96 M(+2.6%) |
| Mar 2023 | - | -$11.26 M(-4.8%) | -$44.77 M(+4.9%) |
| Dec 2022 | -$42.69 M | -$11.82 M(+4.3%) | -$42.69 M(+8.7%) |
| Sep 2022 | - | -$11.33 M(+9.2%) | -$39.28 M(+23.2%) |
| Jun 2022 | - | -$10.37 M(+13.1%) | -$31.89 M(+27.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$9.17 M(+9.0%) | -$24.96 M(+27.5%) |
| Dec 2021 | -$19.58 M(+147.5%) | -$8.41 M(+113.8%) | -$19.58 M(+56.5%) |
| Sep 2021 | - | -$3.93 M(+14.3%) | -$12.51 M(+13.0%) |
| Jun 2021 | - | -$3.44 M(-9.3%) | -$11.07 M(+14.6%) |
| Mar 2021 | - | -$3.79 M(+182.6%) | -$9.66 M(+22.1%) |
| Dec 2020 | -$7.91 M(+1.4%) | - | - |
| Dec 2020 | - | -$1.34 M(-46.1%) | -$7.91 M(+20.4%) |
| Sep 2020 | - | -$2.49 M(+22.4%) | -$6.57 M(+61.0%) |
| Jun 2020 | - | -$2.04 M(-0.5%) | -$4.08 M(+99.5%) |
| Mar 2020 | - | -$2.05 M | -$2.05 M |
| Dec 2019 | -$7.80 M | - | - |
FAQ
- What is Acumen Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Acumen Pharmaceuticals?
- What is Acumen Pharmaceuticals annual EBITDA year-on-year change?
- What is Acumen Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Acumen Pharmaceuticals?
- What is Acumen Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Acumen Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Acumen Pharmaceuticals?
- What is Acumen Pharmaceuticals TTM EBITDA year-on-year change?
What is Acumen Pharmaceuticals annual EBITDA?
The current annual EBITDA of ABOS is -$51.61 M
What is the all time high annual EBITDA for Acumen Pharmaceuticals?
Acumen Pharmaceuticals all-time high annual EBITDA is -$7.80 M
What is Acumen Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, ABOS annual EBITDA has changed by -$8.92 M (-20.89%)
What is Acumen Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of ABOS is -$28.69 M
What is the all time high quarterly EBITDA for Acumen Pharmaceuticals?
Acumen Pharmaceuticals all-time high quarterly EBITDA is -$1.34 M
What is Acumen Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ABOS quarterly EBITDA has changed by -$15.78 M (-122.13%)
What is Acumen Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of ABOS is -$77.89 M
What is the all time high TTM EBITDA for Acumen Pharmaceuticals?
Acumen Pharmaceuticals all-time high TTM EBITDA is -$2.05 M
What is Acumen Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ABOS TTM EBITDA has changed by -$30.34 M (-63.81%)